Q-Line Biotech NSE SME IPO review

The company is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables.
It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments.
As the company has no listed peers, it is trying to extract fancy price for its IPO.
Based on its overall financial data, the issue appears fully priced.
Well-informed investors may park moderate funds for long term.

About Company

Q-Line Biotech Ltd. (QBL) is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs since 2013 directly or through its distributor/s majorly to diagnostic service providers, hospitals and medical colleges.

The company has established its brands over a period of 12 years through its experience, R & D, manufacturing capabilities and quality assurance. The core segments of operations of the Company in IVD Industry include Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids).

QBL’s key manufacturing segments include indigenous manufacturing of reagents including Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids) and supplying/ manufacturing of in-vitro diagnostics (IVD), Pathology equipment’s & devices. Further during the Covid-19 pandemic, the company diversified its focus and with the technical collaboration of third-party institutes and through its own R&D team developed a range of Covid testing kits viz. RT-PCR Kits, RNA Extraction Kits, VTM Kits etc.

It is research driven company engaged in developing and manufacturing a wide range of reagents formulations used across various IVD and diagnostic needs. The company leverages its R&D capabilities to develop and manufacture a portfolio of differentiated reagent formulations /products. Further, for its certain Class of Reagent & equipment’s and devices manufacturing business, the company has entered into technical collaboration with certain international companies. Under the agreement terms, it undertakes the manufacturing of these Reagent and equipment’s and devices as per the technical collaboration and specifications provided by the partners or companies.

With the help of these collaborations the equipment and devices adhere to strict quality control, international standards and certifications. As of March 31, 2026, the company employed 19 personnel at R&D laboratories, which constituted 5.25% of its total permanent employee strength. As of March 31, 2026, it had 362 employees on its payroll and additional 223 contract employees in various departments.

Issue Details / Capital History

The company is coming out with its maiden book building route IPO of 6253200 equity shares of Rs. 10 each to mobilize Rs. 214.48 cr. at the upper cap. The company has announced a price band of Rs. 326 - Rs. 343 per share. The minimum application to be made is for 800 shares and in multiples of 400 shares thereon, thereafter. The IPO opens for subscription on May 21, 2026, and will close on May 25, 2026. The IPO constitute 26.81% of the post-IPO paid-up capital of the company. The shares will be listed on NSE SME Emerge. From the net proceeds of the IPO, it will utilize Rs. 93.50 cr. for working capital, Rs. 90.00 cr. for repayment/prepayment of certain borrowings, and the rest for general corporate purposes.

The company raised Rs. 27.44 cr. in a pre-IPO placement of 800000 shares in May 2026, at Rs. 343 per share.

The IPO is jointly lead managed by Hem Securities Ltd., and Share India Capital Services Pvt. Ltd., Purva Sharegistry (India) Pvt. Ltd., is the registrar to the issue. HEM group’s Hem Finlease Pvt. Ltd., is the market maker as well as a syndicate member.

The company has issued initial equity capital at par value. It raised further equity shares in the price range of Rs. 125 – Rs. 417 between March 2019 and May 2026. It has also issued bonus shares in the ratio of 2 for 1 in March 2016, and 9 for 1 in August 2025. The average cost of acquisition of shares by the promoters is Rs. 0.00, Rs. 0.04, and Rs. 18.34 per share.

Post-IPO, company’s current paid-up equity capital of Rs. 17.07 cr. will stand enhanced to Rs. 23.33 cr. Based on the upper band of the IPO pricing, the company is looking for a market cap of Rs. 800.16 cr.

IPO Lead Managers & Registrar

Financial Performance

On the financial performance front, for the last three fiscals, the company has (on a consolidated basis) posted total income/ net profit, of Rs. 184.81 cr. / Rs. 32.10 cr. (FY23), Rs. 206.45 cr. / Rs. 34.44 cr. (FY24), Rs. 322.58 cr. / Rs. 28.13 cr. (FY25). For 9M of FY26 ended on December 31, 2025, it earned a net profit of Rs. 38.69 cr. on a total income of Rs. 236.50 cr. Though it posted growth in its top lines for the reported periods, its bottom line posted inconsistency. For FY25, it posted lower net profit of Rs. 28.13 cr., and for 9M-FY26, though the top line is Rs, 236.50 cr. it posted bumper profit of Rs. 38.69 cr. in a pre-IPO period, that not only raise eyebrows, but also concern over its sustainability going forward. Despite higher other income for FY25, it marked lower net following extra-ordinary item of Rs. 16.97 cr. Its contingent liability stood at Rs. 61.64 cr. as of December 31, 2025, that raises alarm. Its overall borrowings of Rs. 242.57 cr. as of December 31, 2025, raise concern.

For the last two fiscals, the company has reported an average EPS of Rs. 25.00, and an average RoNW of 23.17%. The issue is priced at a P/BV of 2.44 based on its NAV of Rs. 140.81 per share as of December 31, 2025, but its post-IPO NAV data is missing from the offer documents.

If we attribute FY26 super earnings to its post-IPO fully diluted paid-up equity capital, then the asking price is at a P/E of 15.51, and based on FY25 earnings, the P/E stands at 28.44. The issue appears fully priced, based on its bumper earnings for 9M-FY26, which may not be sustained.

For the reported periods, the company has posted PAT margins of 17.56% (FY23), 16.92% (FY24), 8.97% (FY25), 16.65% (9M-FY26), and RoCE margins of 22.14%, 19.25%, 17.66%, 13.32%, respectively, for referred periods.

All amounts in Indian Rupees crores

Period Ended	Revenue	Expense	PAT	Assets
2023	₹184.81	₹154.97	₹32.10	₹251.58
2024	₹206.45	₹175.85	₹34.44	₹339.25
2025	₹322.58	₹261.43	₹28.13	₹455.49
Dec 2025	₹236.50	₹186.96	₹38.69	₹561.34

Dividend Policy

The company has not paid any dividends for the reported periods of the offer document. It will adopt a prudent dividend policy, based on its financial performance and future prospects.

Comparison with Listed Peers - for Fiscal 2025

As per the offer document, the company has no listed peers to compare with.

Name of the Company	Face Value (₹)	EPS basic (₹)	EPS Diluted (₹)	RONW (%)	P/E Ratio	NAV (₹)
Powerica Limited	5	15.26	15.26	15.37 %	24.45	99.76
Listed Peers
Cummins India Limited	2	72.15	72.15	26.45%	64.13	272.78
Kirloskar Oil Engines Limited	2	33.71	33.60	15.85%	43.24	212.60
NTPC Green Energy Limited	10	0.67	0.67	2.58%	129.40	21.88
Acme Solar Holdings Limited	2	4.55	4.53	5.59%	50.74	74.54
Adani Green Energy Limited	10	8.37	8.37	11.90%	101.53	76.62

Disclaimer: Above table shows earnings and P/E ratio as of 2025-26

Merchant Banker's Track Record

The two merchant bankers associated with this issue have handled 79 issues in the past three years, out of which 8 issues closed below the issue price on listing date.

Conclusion - Apply for medium to long term

QBL is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables. It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments. As the company has no listed peers, it is trying to extract fancy price for its IPO. Based on its overall financial data, the issue appears fully priced. Well-informed investors may park moderate funds for long term.

Dilip Davda is a veteran financial journalist associated with the Indian stock market since 1978. He has been contributing to print and electronic media on capital markets, insurance, and finance since 1985.

He is widely recognized for reviewing public issues and non-convertible debentures (NCDs) in the primary market. Drawing on over three decades of market experience and close interaction with merchant bankers, his reviews focus on detailed fundamental and financial analysis of companies, with a special emphasis on SME public issues.

Disclaimer: The information provided herein is solely for educational and informational purposes and does not constitute an offer, solicitation, or recommendation to buy or sell any securities. Readers are advised to consult a qualified financial advisor before making any investment decisions. Investments in the securities market are subject to market risks. The author does not intend to invest in the securities discussed.

FAQ Accordion

Q-Line Biotech IPO FAQs

1. What is Q-Line Biotech IPO? ⌄

Q-Line Biotech IPO is SME IPO. The company is going to raise ₹214 Crores via IPO. The issue is priced at ₹326 to ₹343 per equity share. The IPO is to be listed on NSE SME.

2. When Q-Line Biotech IPO will open for subscription? ⌄

The IPO is to open on May 21, 2026 for QIB, NII, and Retail Investors. The IPO will close on May 25,2026.

3. What is Q-Line Biotech IPO Investors Portion? ⌄

The investors’ portion for QIB is 50%, NII is 15%, and Retail is 35%.

4. How to Apply the Q-Line Biotech IPO? ⌄

You can apply for Q-Line Biotech IPO via ASBA online via your bank account. You can also apply for ASBA online via UPI through your stock brokers. You can also apply via your stock brokers by filling up the offline form.

5. What is Q-Line Biotech IPO Issue Size? ⌄

Q-Line Biotech IPO issue size is ₹214 crores.

6. What is Q-Line Biotech IPO Price Band? ⌄

Q-Line Biotech IPO Price Band is ₹326 to ₹343.

7. What is Q-Line Biotech IPO Lot Size? ⌄

The minimum bid is 800 Shares with ₹2,74,400 amount.

8. What is the Q-Line Biotech IPO Allotment Date? ⌄

Q-Line Biotech IPO allotment date is May 26,2026.

9. What is the Q-Line Biotech IPO Listing Date? ⌄

Q-Line Biotech IPO listing date is May 29, 2026. The IPO is to list on NSE SME.

Laxmi India Finance IPO Review, Analysis, Good or Bad

By Jagat Joshi
July 28, 2025

Laxmi India Finance IPO is scheduled to open on July 29, 2025, and close on July 31, 2025. The price range for the IPO is ₹150 to ₹158 per share with a face value of ₹5 per share. The company plans to raise about ₹254.26 crores through an initial public offering.

As an investor, deciding whether to apply for or not for an IPO can often be challenging. If you are confused and worried about whether to Apply or Not the Laxmi India Finance IPO. Then worry not, here we are describing 10 important key points & an in-depth, detailed Laxmi India Finance IPO review which will help you to make the decision.

Strengths and Weaknesses of Laxmi India Finance IPO

Strengths:

Laxmi India Finance is one of the leading companies that has access to multiple sources of capital and an effective cost of funds.

The company has shown a strong presence in semi-urban and rural areas using both direct and indirect channels to reach more customers.

The company runs its business smoothly, all due to the hard work of its Promoters, and its Senior Management includes experienced professionals and industry experts.

Laxmi India’s Hub and Branch model makes our operations more efficient, lowers costs, and improves customer access, helping them grow their business and reach more markets.

Weaknesses:

The company runs its business smoothly with a need for a large amount of capital. If any disturbance or delay happens in gathering the funding on good terms can badly impact the company’s financial performance, cash flow, and overall condition.

Laxmi India offers its services to micro, small, and medium enterprises (MSMEs). If any changes happen in this sector or government policies can badly impact the business, cash flow, and overall condition.

The company must follow certain terms and conditions under the loan agreement. If unable to meet these conditions, it can result withdrawal of the credit facilities, or we might have to repay the loans earlier can impact the overall business.

The company generates most of its revenue with mid to low-income customers in rural and semi-urban parts of India, which are affected by tough economic conditions. If these customers are unable to repay on time can badly impact the business, overall performance, and cash flow.

Details of Laxmi India Finance IPO

IPO Size	₹254.26 crores
Offer-for-sale	up to 56,38,620 equity shares
Fresh issue	₹165.17 crores
Price band	₹150 to ₹158
Subscription	Opens on July 29, 2025, and the closing date is July 31, 2025
Purpose of IPO	Fresh Issue and Offer-for-Sale

Laxmi India Finance IPO Open and closing date?

The opening date of Laxmi India Finance IPO is July 29, 2025, and the closing date is July 31, 2025.

What is the size of the Laxmi India Finance IPO?

Laxmi India Finance decided to raise around ₹254.26 crores through an IPO. This IPO is entirely a fresh issue of ₹165.17 crores and an Offer-for-sale up to 56,38,620 equity shares, with a face value of ₹5 each.

What are the subscription details of the Laxmi India Finance IPO?

Laxmi India Finance IPO price band is set at ₹150 to ₹158 per share. In this IPO, a total of 94 shares were available in 1 lot size for the minimum Retail category, and for the maximum retail category, 1,222 shares in 13 lot sizes were available. For the S-HNI Minimum category, 1,316 shares were available in 14 lot sizes. While for the B-HNI Minimum category 6,392 shares were available in 68 lot sizes.

To invest in this IPO, each investor category has specific investment amounts:

Retail Investors: Minimum investment of ₹14,852 and maximum investment of ₹1,93,076.
Small HNI (S-HNI): Minimum investment of ₹2,07,928.
Big HSI (S-HNI): A minimum investment of ₹10,09,936 is required.

What is the Laxmi India Finance IPO listing Date?

Laxmi India Finance is a Mainboard IPO whose shares will be listed on August 5, 2025, on the BSE (Bombay Stock Exchange) & NSE (National Stock Exchange).

What are the objectives of the Laxmi India Finance IPO Issue?

The main reason behind raising funds via a fresh issue is to strengthen its capital base to support our future funding needs for onward lending. Lastly, the remaining funds will be utilized for the company’s general corporate purposes.

About Laxmi India Finance

Incorporated in 1996, Laxmi India Finance Limited is one of the growing companies engaged in the business of a Non-Banking Financial Company. Laxmi India is involved in providing MSME loans, vehicle loans, construction loans, and other lending products to small businesses and entrepreneurs. As of June 30, 2024, the company comprises 26,065 customers, including 15,732 active MSMEs and 6,146 active vehicle loan customers. As of September 30, 2024, the company includes a team of 255 people who use a special app to track repayments, loan defaults, and overdue payments in real-time. As of September 30, 2024, the company includes 139 branches in Rajasthan, Gujarat, Madhya Pradesh, and Chhattisgarh.

Laxmi India Finance Financials

The company reported revenue of ₹248.04 crores in 2025 against ₹175.02 crores in 2024. The company reported a profit of ₹36.01 crores in 2025 against a profit of ₹22.47 crores in 2024.

Laxmi India Finance IPO Promoters

Deepak Baid, Prem Devi Baid, Aneesha Baid, Hirak Vinimay Private Limited, Deepak Hitech Motors Private Limited, Prem dealers Private Limited, and Vivan Baid Family Trust are the promoters of the company.

Who are the Laxmi India Finance IPO lead managers and registrar?

PL Capital Markets Private Limited is Laxmi India Finance’s lead manager, while MUFG Intime India Private Ltd is the company’s registrar.

Should you Apply or not for the Laxmi India Finance IPO?

Laxmi India Finance is one of the leading non-banking financial companies, is aiming to raise ₹254.26 crores through an IPO that includes both fresh issuance (₹165.17 crore) and an offer‑for‑sale by existing shareholders (₹89.09 crore). The price band is set at ₹150 to ₹158 per share.

The company’s portfolio comprises MSME loans, vehicle loans, construction loans, and other lending products serving the diverse needs of its customers. The aim behind lending MSME loans to small businesses and entrepreneurs is to drive economic growth and support financial inclusion. The company is planning to utilize its funds to strengthen its capital base to support its future funding needs for giving out more loans. Now, if you ask whether you should apply or not for the Laxmi India Finance IPO, then there are some risk factors one must keep in mind: the company runs in a concentrated geographic footprint, and the company mostly runs its business with dependencies on MSME and vehicle loans. It could face issues if borrowers default or if there are changes in rules for NBFCs.

We recommend that investors only apply for this IPO after checking the company’s financial background, risks, and deciding whether to apply for the IPO or not.

Jagat Joshi

Founder of IPOWatch, brings nearly 15 years of experience in IPO analysis and market research. He provides complete coverage of upcoming IPOs, subscription trends, grey market premiums (GMP), and post-listing performance, along with easy-to-understand reviews, insights, and analysis. In his working journey, he has worked with various platforms and received expertise in stock market analysis and primary markets.